- Home
- CYBN vs PTMN Comparison
CYBN vs PTMN Comparison
Compare CYBN & PTMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYBN
- PTMN
- Stock Information
- Founded
- CYBN 2019
- PTMN 2006
- Country
- CYBN Canada
- PTMN United States
- Employees
- CYBN N/A
- PTMN N/A
- Industry
- CYBN Pharmaceuticals and Biotechnology
- PTMN Finance: Consumer Services
- Sector
- CYBN Health Care
- PTMN Finance
- Exchange
- CYBN Nasdaq
- PTMN Nasdaq
- Market Cap
- CYBN 177.9M
- PTMN 156.9M
- IPO Year
- CYBN N/A
- PTMN N/A
- Fundamental
- Price
- CYBN $9.13
- PTMN $16.42
- Analyst Decision
- CYBN Strong Buy
- PTMN Hold
- Analyst Count
- CYBN 3
- PTMN 3
- Target Price
- CYBN $138.00
- PTMN $19.33
- AVG Volume (30 Days)
- CYBN 213.0K
- PTMN 37.9K
- Earning Date
- CYBN 02-12-2025
- PTMN 03-12-2025
- Dividend Yield
- CYBN N/A
- PTMN 16.81%
- EPS Growth
- CYBN N/A
- PTMN N/A
- EPS
- CYBN N/A
- PTMN 0.39
- Revenue
- CYBN N/A
- PTMN $65,828,000.00
- Revenue This Year
- CYBN N/A
- PTMN N/A
- Revenue Next Year
- CYBN N/A
- PTMN N/A
- P/E Ratio
- CYBN N/A
- PTMN $42.56
- Revenue Growth
- CYBN N/A
- PTMN N/A
- 52 Week Low
- CYBN $6.50
- PTMN $15.94
- 52 Week High
- CYBN $19.84
- PTMN $20.84
- Technical
- Relative Strength Index (RSI)
- CYBN 45.18
- PTMN 48.10
- Support Level
- CYBN $8.83
- PTMN $16.05
- Resistance Level
- CYBN $9.41
- PTMN $16.38
- Average True Range (ATR)
- CYBN 0.59
- PTMN 0.24
- MACD
- CYBN -0.02
- PTMN 0.04
- Stochastic Oscillator
- CYBN 31.74
- PTMN 84.21
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.
About PTMN Portman Ridge Finance Corporation
Portman Ridge Finance Corp Inc is a non-diversified closed-end investment company. The company originates, structures, and invests in secured term loans, bonds or notes, and mezzanine debt primarily in privately-held middle market companies but may also invest in other investments such as loans to publicly traded companies, high-yield bonds, and distressed debt securities. The company's investment objective in the Debt securities portfolio is to generate current income and, to a lesser extent, capital appreciation from the investments in senior secured term loans, mezzanine debt, and selected equity investments in privately-held middle market companies.